Menu Search
Equities

Roche Holding AG

RO:SWX

Roche Holding AG

Actions
  • Price (CHF)404.80
  • Today's Change3.00 / 0.75%
  • Shares traded35.23k
  • 1 Year change+32.46%
  • Beta--
Data delayed at least 15 minutes, as of Dec 08 2021 16:38 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in -- (TTM)--
  • Net income in --
  • Incorporated1966
  • Employees--
  • Location
    Roche Holding AGGrenzacherstr. 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttp://www.roche.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ROG:SWX since
announced		Transaction
value
GenMark Diagnostics IncDeal completed15 Mar 202115 Mar 2021Deal completed22.46%1.84bn
Data delayed at least 15 minutes, as of Dec 08 2021 16:39 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.